文献速递妇科产科

MSK衰弱指数与老年卵巢癌手术决策、临床试验参与及总生存的关联

Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-03-25

该回顾性研究对2001至2017年间在本机构接受手术治疗的430例≥70岁新诊断晚期卵巢癌患者应用MSK衰弱指数(MSK-FI),发现衰弱程度越高,患者接受初次肿瘤细胞减灭术(PDS)的可能性越低(OR 0.64,95%CI 0.53-0.77,p<0.0001),且更可能延迟术后化疗、较少参与临床研究(OR 0.84,95%CI 0.70-1.00,p=0.049),总生存更差(HR 1.16,95%CI 1.05-1.30,p=0.005)。

要点

  • 衰弱与术后化疗延迟呈非线性关联(p=0.009)。
  • 衰弱程度越高,总生存越差(HR 1.16,p=0.005)。

核心结论

  • 由MSK-FI计算的衰弱与老年晚期卵巢癌患者的治疗方式强烈相关,提示MSK-FI的客观或主观相关因素影响决策。

研究设计与样本

  • 回顾性队列研究,纳入2001年1月至2017年5月在本机构接受手术治疗的≥70岁新诊断晚期卵巢癌女性,共430例,MSK-FI包含10种合并症和功能评估,评分范围0-11分。

主要发现

  • 430例中接受PDS者231例(54%),接受新辅助化疗/间歇性肿瘤细胞减灭术者199例(46%)。
  • MSK-FI评分分布:0分95例(22%),1分172例(40%),2分89例(21%),3分及以上74例(17%)。
  • MSK-FI每增加1分,接受PDS的OR为0.64(95%CI 0.53-0.77,p<0.0001)。
  • 3级及以上并发症和计划外重症监护入住分别发生于40例(9%)和38例(9%),与衰弱无关联(OR 1.21,95%CI 0.96-1.52,p=0.11)。
  • 衰弱程度越高,术后化疗延迟越可能(非线性关联p=0.009),参与研究越少(OR 0.84,95%CI 0.70-1.00,p=0.049),总生存越差(HR 1.16,95%CI 1.05-1.30,p=0.005)。

临床怎么用

  • 对老年晚期卵巢癌患者,MSK-FI可作为评估衰弱并辅助手术决策的参考工具。
  • 衰弱评估有助于识别可能延迟术后化疗或总生存较差的患者,便于个体化咨询。

局限性

  • 回顾性研究,MSK-FI从医疗记录中提取,可能存在信息偏倚。
  • 单中心研究,样本量430例,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine whether the Memorial Sloan Kettering Frailty Index (MSK-FI) is associated with decision-making in older women surgically treated for advanced-stage ovarian cancer. METHODS: We retrospectively applied the MSK-FI to women ≥70 years with newly diagnosed advanced-stage ovarian cancer surgically treated at our institution from 01/2001-05/2017. MSK-FI components, including 10 comorbidities and functional assessment, were extracted from medical records. The MSK-FI ranges from 0 to 11, with higher scores indicating greater frailty. The primary outcome was the association between frailty and rate of primary debulking surgery (PDS), for which a multivariable logistic regression was used, adjusted for stage and histology. RESULTS: We identified 430 women treated with PDS (n = 231, 54%) or neoadjuvant chemotherapy/interval debulking (n = 199, 46%) with complete data. MSK-FI score distribution was: "0", 95 patients (22%); "1", 172 (40%); "2", 89 (21%); and "3+", 74 (17%). More-frail patients were less likely to have undergone PDS (OR for a unit increase of MSK-FI: 0.64; 95%CI, 0.53-0.77; p < 0.0001). Grade 3+ complications and unintended intensive care admission occurred in 40 (9%) and 38 (9%) women, respectively, but were not associated with frailty (OR 1.21; 95%CI, 0.96-1.52; p = 0.11). More-frail patients were more likely to delay postoperative chemotherapy (non-linear association p = 0.009) and less likely to enroll in research (OR 0.84; 95%CI, 0.70-1.00; p = 0.049). Greater frailty was associated with poorer overall survival (HR 1.16; 95%CI, 1.05-1.30; p = 0.005). CONCLUSIONS: Frailty, as calculated by the MSK-FI, is strongly associated with treatment approach in older women with advanced ovarian cancer, suggesting objective or subjective correlates of the MSK-FI influence decision-making.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Filippova OT, Tin AL, Alonso J, et al. Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. Gynecol Oncol. 2021. PMID: 33773807. doi:10.1016/j.ygyno.2021.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。